Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359561 | 0.80 | HTR2C (0.54) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL2176001 | 0.77 | HTR2C (0.46) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| Hydrochloric Acid SCHEMBL15379330 | 0.76 | HTR2C (0.47) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL7482242 | 0.76 | HTR2C (0.47) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| Hydrochloric Acid SCHEMBL9310529 | 0.74 | HTR2C (0.58) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL5138820 | 0.74 | HTR2C (0.58) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL6595415 | 0.74 | ADRA2A (0.40) | DRD2ADRA2AADRA2B | |
| SCHEMBL19297061 | 0.73 | HTR2C (0.53) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| Bromide SCHEMBL9325877 | 0.73 | HTR2C (0.56) | HTR2CKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL5153625 | 0.72 | ADRA2A (0.56) | KDM4EALDH1A1MAPTDRD2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3115361-B1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-10-23 | — | — | EP | disclosed |
| US-10174011-B2 | Heterocyclic compounds, process for preparation of the same and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-08 | — | — | US | disclosed |
| EP-3115361-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015131856-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2015-09-11 | — | — | WO | disclosed |
| EP-1204660-B1 | SEROTONERGIC BENZOTHIOPHENES | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174011-B2 | Heterocyclic compounds, process for preparation of the same and use thereof | CYP11B2, CYP11B1, ADCYAP1R1 | HTR2C 333/4885KDM4E 2810/4885ALDH1A1 485/4885 |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | CYP11B2, CYP11B1, ADCYAP1R1 | HTR2C 333/4885KDM4E 2810/4885ALDH1A1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.